Altamira Therapeutics Ltd. Basic Earnings Loss Per Share From Discontinued Operations
Altamira Therapeutics Ltd. (CYTOF) reported Basic Earnings Loss Per Share From Discontinued Operations of 6.92 CHF/shares for the 12-month period ending 2023-12-31, per its 20-F/A filed 2024-04-22.
Financial Statements › Income Statement › Earnings Per Share
ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations · last filed 2025-04-30
CHF/shares
| Period end | Basic Earnings Loss Per Share From Discontinued Operations 12 month | Basic Earnings Loss Per Share From Discontinued Operations 12 month as first filed |
|---|---|---|
| 2023-12-31 | 6.92 CHF/shares 20-F/A · filed 2024-04-22 | |
| 2022-12-31 | -172.98 CHF/shares 20-F/A · filed 2024-04-22 | -29.13 CHF/shares 20-F · filed 2023-05-16 |
| 2021-12-31 | -313.15 CHF/shares 20-F/A · filed 2024-04-22 | -25.76 CHF/shares 20-F · filed 2023-05-16 |
| 2020-12-31 | -27.27 CHF/shares 20-F · filed 2023-05-16 |
USD/shares
| Period end | Basic Earnings Loss Per Share From Discontinued Operations 12 month |
|---|---|
| 2023-12-31 | $7.70 20-F · filed 2025-04-30 |
| 2022-12-31 | -$181.13 20-F · filed 2025-04-30 |